Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers.
This live web broadcast of the PeerView Virtual Seminar and Workshop will provide participating pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, our expert panel will review evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments will focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer.
- Welcome, Introduction, and “Chair’s Take”
- Virtual Seminar
- The Expanding Immunotherapy Landscape and Key Biomarker Alignments in Solid Tumor Oncology: Where Are We Now, Where Are We Going Next, and What Do Pathologists Need to Know?
- Virtual Workshop
- Best Practices for Cancer Immunotherapy Biomarker Testing: What Do Pathologists Need to Do?
- Nuances of PD-L1 Expression Testing
- Strategies for MSI/MMR Status Assessment
- Practicalities of TMB Measurement
- Synthesis, Reflections, and Conclusions
This activity has been designed to meet the educational needs of pathologists, oncologists, and other clinicians involved in the management of precision cancer immunotherapy and immunotherapy biomarkers and/or involved in cancer immunotherapy biomarker testing and treatment individualization.
Upon completion of this activity, participants should be better able to:
- Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies
- Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances
- Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings
- Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology
This CME/MOC/CC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The activity titled 'Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists' has been registered to offer 1.0 Lifelong Learning (Part II) credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
Participation information will be shared with ABPath through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.
Kurt Schalper, MD, PhD
Assistant Professor of Pathology and Medicine
Yale School of Medicine
Director Translational Immuno-oncology Laboratory
Yale Cancer Center
New Haven, Connecticut
Sanjay Mukhopadhyay, MD
Director, Pulmonary Pathology
Department of Pathology
Cleveland Clinic
Robert J. Tomsich Pathology and Laboratory Medicine Institute
Cleveland, Ohio
Sandip Patel, MD
Associate Professor
Deputy Director, San Diego Center for Precision Immunotherapy
Director, Clinical Trials Office
Division of Hematology and Oncology, Department of Medicine
UC San Diego Moores Cancer Center
La Jolla, California
The Medical Learning Institute, Inc. (MLI) requires faculty, planners, staff, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they, and their spouse/life partners, may have as related to the content of this activity. These disclosures will be provided to learners prior to the start of the activity. All identified COI are thoroughly vetted and resolved according to MLI policy. MLI is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.
Please note that if you are requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID/ABPath Diplomate ID number & DOB (MM/DD). A score of 70% or higher is needed to obtain MOC/CC credit.
Copyright © 2000-2020, PeerView